Background: Naloxone is effective for reversing opioid overdose, but optimal strategies for out-of-hospital use are uncertain.
S
ince 2000, the rate of drug overdose deaths involving opioids has increased 4-fold (1, 2) . Overdose is now the leading cause of injury-related death in the United States (3) . In 2015, the number of overdose deaths involving prescription or illicit opioids exceeded 33 000, the highest number on record (2) .
Opioid overdose is frequently treated with naloxone in out-of-hospital settings by emergency medical services (EMS) personnel and laypersons. Although recommendations, guidelines, and protocols are available to inform use of naloxone in out-of-hospital settings, uncertainties exist with regard to the optimal dosing and route of administration and management after successful reversal of opioid overdose (4 -6) . A recent concern is whether current dosing guidelines are sufficient for reversing overdose involving highly potent synthetic opioids, such as fentanyl and fentanyl analogues (2, (7) (8) (9) (10) (11) . The purpose of this systematic review was to synthesize the evidence on 1) the effects of route of administration and dosing of naloxone in persons with suspected opioid overdose in out-of-hospital settings on mortality, reversal of overdose symptoms, and harms, and 2) the need for transport to a health care facility after naloxone reversal. This review was conducted as part of a systematic review that was nominated to the Agency for Healthcare Research and Quality (AHRQ) by the National Highway Traffic Safety Administration.
METHODS
Detailed methods and data for this review, including the analytic framework, key questions, search strategies, inclusion criteria, study data extraction, and quality ratings, are available in the full report (12) . The protocol was developed using a standardized process (13) with input from experts and the public and is registered in the PROSPERO database (14) . The analytic framework used to guide this review is shown in Figure 1 .
We addressed the following key questions: 1. For patients with confirmed or suspected opioid overdose, what are the comparative benefits and harms of out-of-hospital administration of naloxone using intravenous, intramuscular, subcutaneous, and intranasal routes of administration?
1a. For patients with confirmed or suspected opioid overdose who receive naloxone in out-of-hospital settings, what are the comparative benefits and harms of different intravenous, intramuscular, subcutaneous, or intranasal doses of naloxone?
2. For patients with confirmed or suspected opioid overdose in out-of-hospital settings, what are the comparative benefits and harms of titration of naloxone until the patient resumes sufficient spontaneous respiratory effort versus until the patient regains consciousness?
3. For patients with confirmed or suspected opioid overdose in out-of-hospital settings treated with multiple doses of naloxone (including those who do not improve after an initial dose of intranasal naloxone), what are the effects on benefits and harms of differences in the timing of repeated dosing?
4. For patients with confirmed or suspected opioid overdose in out-of-hospital settings who regain sufficient spontaneous respiratory effort and are alert and oriented after naloxone administration, what are the benefits and harms of transport to a health care facility versus nontransport?
Data Sources and Searches
A research librarian searched multiple electronic databases, including Ovid MEDLINE (1946 through September 2017), PsycINFO, the Cochrane Central Register of Controlled Trials, and CINAHL. We also reviewed reference lists, searched ClinicalTrials.gov (through September 2017), contacted representatives of federal agencies involved in naloxone or opioid overdose research, reviewed medical and statistical reviews on the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research Web site, and reviewed materials presented at a recent FDA meeting (15) on naloxone dosing (16 -21).
Study Selection
Two investigators independently reviewed abstracts and full-text articles against prespecified eligibility criteria. We included randomized controlled trials (RCTs) and cohort studies comparing different routes of administration, doses, or dosing strategies for naloxone and studies on the effects of transport or nontransport after successful reversal of opioid overdose with naloxone in out-of-hospital settings. Naloxone could be administered by EMS personnel, other health care providers, or laypersons. We also included studies on dosing and routes of administration in emergency department (ED) settings. We included uncontrolled longitudinal studies of patients who were successfully treated for opioid overdose with naloxone in the field and were not transported to a health care facility; this was a protocol modification due to no controlled studies of transport versus nontransport. Outcomes were mortality, reversal of overdose symptoms (based on adequate spontaneous respiratory effort or level of consciousness), time to reversal of symptoms, recurrence of symptoms, cardiac or respiratory arrest, other clinical sequelae of overdose (such as noncardiogenic pulmonary edema), function, quality of life, health care use, and harms (such as drug withdrawal, combativeness, or injury to the person administering naloxone). For key question 4, additional outcomes were rates of linkage to treatment for opioid use disorder and subsequent opioid overdoses.
Data Extraction and Quality Assessment
One investigator extracted details about the design, year, setting, country, sample size, eligibility criteria, population and clinical characteristics, intervention characteristics (route of administration, dose or concentration, time to initial and repeated dosing, and training and background of personnel administering the drug), funding source, and results. A second investigator verified extractions for accuracy.
Two investigators independently assessed risk of bias for each study as low, moderate, or high using criteria adapted from the Methods Guide for Effectiveness and Comparative Effectiveness Reviews (13) and the U.S. Preventive Services Task Force (22) . Discrepancies were resolved through discussion and consensus.
Data Synthesis and Analysis
We constructed evidence tables with study characteristics, results, and risk-of-bias ratings for all included studies and summary tables to highlight the main findings. Given the small number of studies for each key question and clinical and methodological heterogeneity of the studies, we determined that meta-analysis was not indicated and synthesized studies qualitatively.
We graded the strength of evidence (SOE) for each key question and comparison for prioritized clinical outcomes (mortality, time to reversal of symptoms, recurrence of symptoms, respiratory or cardiac arrest, rates and severity of drug withdrawal, and combativeness) using the approach described in the Methods Guide for Effectiveness and Comparative Effectiveness Reviews (13) . One investigator performed initial SOE assessments, and final ratings were determined by consensus among the entire team.
Role of the Funding Source
This project was funded under contract no. HHSA290-2015-00009-I from the AHRQ, U.S. Department of Health and Human Services. Staff from the AHRQ assisted in developing the scope and key questions. A representative from the AHRQ served as a Contracting Officer's Technical Representative and provided technical assistance during the conduct of the full evidence report and comments on draft versions of the report. The AHRQ did not directly participate in the literature search, determination of study eligibility criteria, data analysis, or interpretation.
RESULTS

Literature Searches
The literature flow diagram ( Figure 2 ) summarizes the search and selection of articles. Database searches (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . No study reported funding from manufacturers of naloxone.
Routes of Naloxone Administration
Three RCTs (n = 100 to 182) (23-25) and 4 cohort studies (n = 93 to 609) (26 -29) compared different routes of naloxone administration (Appendix Tables 1  and 2 ). All studies had methodological shortcomings, including unblinded design and baseline betweengroup differences; the cohort studies also did not adjust for potential confounders or report attrition (risk-ofbias ratings are shown in Appendix Tables 4 and 5, available at Annals.org).
Two Australian trials compared out-of-hospital intranasal versus intramuscular naloxone administration but evaluated intranasal formulations not used in the United States (23, 24) . One trial compared intranasal naloxone (2 mg/mL) versus intramuscular naloxone (2 mg). There was no difference in the likelihood of adequate response (defined as effective and spontaneous respiration at a rate ≥10 breaths/min or a Glasgow One trial and 2 cohort studies compared intranasal versus intravenous naloxone (25-27). The trial, which was conducted in an Iranian ED setting, found that intranasal naloxone (0.4 mg/2 mL) was associated with a greater likelihood of an adequate response (defined as a level of consciousness of "lethargic" or "conscious" after treatment) than intravenous naloxone (0.4 mg) (100% vs. 60%; RR, 1.7 [CI, 1.3 to 2.1]) and a lower likelihood of agitation (0% vs. 24%; RR, 0.04 [CI, 0.002 to 0.66]) (25). Applicability of this study to U.S. field settings is limited by the ED setting and the high proportion of opium-related overdoses. The cohort studies reported few differences between intranasal and intravenous naloxone, but both had serious methodological shortcomings (Appendix Table 5 ) (26, 27).
Other comparisons involving different routes of administration were evaluated in 1 cohort study each. One found no difference in the likelihood of a positive response (GCS score ≥14 and respiratory rate ≥10 breaths/min within 5 minutes of administration) between intramuscular and intravenous naloxone (94% vs. 95%; RR, 1.0 [CI, 0.94 to 1.1]) (28) . The other found that subcutaneous naloxone was associated with longer time from administration to a respiratory rate of at least 10 breaths/min (5.5 vs. 3.8 minutes; P = 0.001) than intravenous naloxone but no difference in time from arrival at the patient's side to a respiratory rate of at least 10 breaths/min (9.6 vs. 9.3 minutes; P = 0.67) (29) . Subcutaneous naloxone was associated with a lower likelihood of a need for multiple doses than intravenous naloxone (15% vs. 35%; RR, 0.42 [CI, 0.25 to 0.71]).
No study evaluated how comparative benefits and harms of different routes of administration differed according to demographic characteristics, overdose factors (for example, type or dose of opioid involved, presence of other drugs or substances, time since overdose, concomitant psychiatric comorbidities, or prior overdose), or the background or level of training of the person administering naloxone. Two trials (23, 24) and 1 cohort study (26) reported that naloxone was administered by paramedics or advanced life support personnel; 1 cohort study (29) reported the level of training of EMS personnel as ranging from basic to advanced life support.
Naloxone Dose or Formulation
No study directly compared different naloxone doses or formulations administered by the same route. Rather, comparisons involving dose or formulation are indirect, based on studies comparing different routes of administration.
In 2 RCTs of intranasal versus intramuscular naloxone, the intranasal concentration was 2 mg/5 mL in 1 trial and 2 mg/mL in the other, although the total dose administered (2 mg) was the same (23, 24) (Appendix Table 1 ). The different concentrations could help explain the different results, given a maximum volume of 0.5 mL absorbed by each nostril (36, 37) . Therefore, the effective (bioavailable) dose of naloxone was probably lower in the trial that used a lower-concentration formulation than in the trial that used a higher-concentration formulation. No study evaluated the new FDAapproved, highly concentrated reformulations of naloxone (2 or 4 mg/0.1 mL).
In 1 RCT (25) and 2 cohort studies (26, 27) of intranasal versus intravenous naloxone, the doses and formulations varied or were not well-described (Appendix Tables 1 and 2 ). The RCT compared intranasal naloxone (0.4 mg/2 mL, at a dose of 0.2 mg/nostril) versus intravenous naloxone (0.4 mg). The 2 observational studies did not report the concentration of the intranasal formulation (2-mg dose), and the intravenous dose ranged from 0.4 to 2.0 mg or was not reported. Therefore, it was not possible to reach reliable conclusions about the comparative effects of different naloxone doses and formulations from these studies.
Titration of Naloxone Dose
No study compared benefits and harms of titration of naloxone until resumption of sufficient spontaneous respiratory effort versus until return to consciousness. One RCT defined a response not requiring repeated administration as an improvement in respiratory rate of at least 10 breaths/min and a GCS score of at least 13 (24) . Other studies that compared different routes of administration had unspecified or unclear titration targets.
Repeated Naloxone Doses
No study compared benefits and harms of differences in timing of repeated dosing of naloxone. Among 5 studies (23-25, 28, 29) that compared different routes of administration, timing of repeated dosing was 1 to 2 minutes in 1 study (28) and 5 to 10 minutes in the others. Because of other differences between trials (such as different doses and formulations, routes of administration, and study design), it was not possible to assess the effects of different redosing intervals on effectiveness.
Hospital Transport After Naloxone Administration
No study compared outcomes between persons transported to a hospital after successful reversal of opioid overdose with naloxone and those who were not transported. Six studies (n = 84 to 2241) reported outcomes in patients not transported to a health care facility after successful naloxone treatment (30 -35) (Appendix Table 3 ). One study was conducted in Finland (30), 1 was done in Denmark (35) , and the others were conducted in the United States. In the U.S. studies, patients declined transport to a health care facility. In the European studies, reasons for nontransport were unclear or varied (physician discretion or patient refusal). Emergency medical services records were used to ascertain naloxone administration, and medical examiner databases, cardiac arrest registries, and hospital records were used to assess outcomes. The studies did not describe how long patients were observed after successful reversal of overdose. All of the studies were rated as having high risk of bias due to uncontrolled design, failure to blind outcome assessors to exposure status, and failure to report missing data (Appendix Table 5 ). The uncontrolled design makes interpretation of findings difficult, given likely differences between persons who decline transport and those who are transported.
Within 0 to 2 days of naloxone administration, 3 studies (n = 317, 552, and 998) reported 0 deaths (32-34); 1 study (n = 205) reported 1 death (0.49%) (31); and 1 study (n = 2241) reported 14 deaths (0.6%), of which 3 were attributed to a likely rebound overdose, 10 were attributed to a new overdose, and 1 was attributed to natural causes (35) . One study (n = 84) reported 1 life-threatening adverse event (1.2%) (30) . One study (n = 205) reported 2 additional deaths at 30 days (1%) (31) , and another (n = 552) identified 9 deaths through up to 1 year (1.6%) (34) . No study evaluated outcomes of linkage to treatment for opioid use disorder or subsequent opioid overdoses.
DISCUSSION
Although naloxone is generally effective at reversing suspected opioid overdose, evidence to inform optimal management of suspected overdose with naloxone in out-of-hospital settings is limited (Table) . At the same dose (2 mg), 1 trial found that a higherconcentration intranasal formulation (2 mg/mL) (23, 24) has efficacy similar to that of intramuscular naloxone, but another trial found that a lower-concentration intranasal formulation (2 mg/5 mL) is less effective (low SOE) (23) . This is consistent with the low bioavailability of the lower-concentration intranasal formulation, given a maximum effective volume of intranasal delivery of 0.5 mL/nostril (36, 37) . Efficacy was based on effects on overdose symptoms (likelihood of an adequate response, time to reversal, and recurrence of symptoms). The trials did not evaluate effects on health care use or other clinical outcomes (such as function or quality of life) and were not designed to assess risk for serious injuries (such as needlestick), although no cases were reported.
Evidence was insufficient to evaluate other comparisons of route of administration of naloxone, due to serious methodological limitations and limited applicability to U.S. field settings (for example, a trial conducted in an Iranian field setting in which a high proportion of opioid overdoses were due to opium use) (25). No study compared effects of different doses via a given route of administration, alternative dose titration strategies, or differences in timing of repeated dosing.
Evidence was also insufficient to reliably determine effects of hospital transport versus nontransport after successful treatment of opioid overdose. Although 6 studies reported low rates (0% to 1.25%) of death or serious adverse events among patients not transported to a health care facility after reversal of opioid overdose with naloxone (30 -35) , there was no comparison group of transported patients. This makes interpretation challenging because nontransported persons are likely to be at lower risk for opioid overdose-related complications than transported patients. For example, 1 study reported that 100% of patients who were not transported to an ED had a GCS score of 14 or 15 after naloxone administration, compared with about half of transported patients (30) . The studies relied on medical examiner and hospital records to identify serious outcomes, which could have resulted in underestimation of events, and were not designed to evaluate outcomes of linkage to treatment for opioid use disorder or subsequent opioid overdoses.
Our findings are consistent with those of a systematic review that found a total of 4 deaths due to rebound opioid toxicity among 5443 patients (38) not transported after reversal of opioid overdose with naloxone (38) . We identified no previously published sys-tematic reviews on the other key questions we addressed. A committee convened by the FDA that focused on naloxone devices intended for use by laypersons (15) also found a lack of evidence to determine optimal dosing (39) . The primary basis for FDA approval of the autoinjector was bioavailability similar to that with a standard syringe (40) . For the highly concentrated intranasal formulation, approval was based on bioavailability that exceeded that of a 0.4-mg intramuscular dose and was similar to that of a 2-mg intramuscular dose (the highest recommended initial intramuscular dose of naloxone) (41) .
Our review had limitations. Few or no studies addressed the key questions, and all studies had methodological limitations. In addition, applicability was limited because all studies evaluated older formulations of naloxone. No study evaluated FDA-approved autoinjectors, at a dose of either 0.4 or 2 mg. Similarly, no study evaluated recently FDA-approved formulations of highly concentrated intranasal naloxone, and 1 trial evaluated intranasal naloxone at a lower concentration (2 mg/5 mL) than what is commonly used off-label in the United States (2 mg/2 mL) (23) . In almost all studies, characteristics of the overdose were not reported, and studies were conducted before the recent increase in availability of high-potency synthetic opioids. No study evaluated how the background or level of training of the person administering naloxone affected outcomes.
Additional research is urgently needed to optimize administration of naloxone in out-of-hospital settings. Trials in U.S. field settings that compare FDA-approved intranasal formulations versus intramuscular autoinjec- tors, FDA-approved versus non-FDA-approved formulations (for example, a 2-mg-per-2-mL intranasal formulation), and different doses by a given route of administration are needed. An ongoing nonrandomized study of EMS providers in New York is comparing intranasal naloxone, 2 mg/2 mL and 4 mg/0.1 mL administered in alternating weeks (42) . Ideally, studies would include and assess (to the extent possible) information on the opioids involved in the overdoses and other confounding factors. Randomized controlled trials in field settings could pose ethical and logistical challenges, such as requiring an exception from informed consent or requiring that consent be obtained before an overdose, which could be difficult in at-risk populations. Although the FDA previously did not approve an investigational new drug application for a randomized trial comparing different routes of naloxone administration (43), regulatory barriers to such studies could be reduced by the availability of new FDA-approved formulations and uncertainty about optimal administration. Future research could also leverage existing EMS registries (44) with naloxone administration data. Ideally, registry studies should include information about the dose, formulation, and route of administration of naloxone; the opioid involved in the overdose; the training of the EMS personnel administering naloxone; clinical response to initial and repeated dosing; protocols for initial and repeated dosing; and clinical outcomes, including response rates using predefined criteria, risk for recurrence of overdose symptoms, and adverse outcomes. Similar data collection standards could be implemented in addition to new national initiatives to decrease opioid overdose (45, 46) .
Research is also needed to determine the optimal timing of repeated dosing and whether to administer doses until the patient is fully conscious or has adequate respiration. Studies should clearly define naloxone dosing protocols, including indications for additional "rescue" dosing.
Randomized trials to understand outcomes of nontransport after successful treatment of opioid overdose with naloxone may not be logistically or ethically feasible. Comparative observational studies could match patients who are not transported to a hospital with those who are transported on the basis of clinical and demographic factors, including the opioid suspected to be involved in the overdose and response to naloxone. To identify outcomes, studies should supplement use of medical examiner and hospital records with formal follow-up assessments and include such outcomes as linkage to treatment for opioid use disorder and risk for future overdose in addition to serious adverse outcomes, such as death.
In conclusion, higher-concentration intranasal naloxone (2 mg/mL) seems to have efficacy similar to that of intramuscular naloxone (2 mg) for reversal of opioid overdose symptoms, with no difference in adverse events. Research is needed on the comparative effectiveness of the recently FDA-approved naloxone autoinjectors and highly concentrated intranasal reformulation, different doses, and dosing strategies. Nontransport of patients after successful reversal of overdose with naloxone seems to be associated with a low rate of serious harms, but no study evaluated the risks associated with transport versus nontransport. 
